Joerg Bernhard Schulz

Joerg Bernhard Schulz

Auto-generated profile, based on publicly available information

Joerg Bernhard Schulz

Department of Neurology RWTH Aachen University Aachen Germany

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
IMI. G. McKeith
I. G. McKeith
DDD. W. Dickson
D. W. Dickson
JLJ. Lowe
J. Lowe
MEM. Emre
M. Emre
JOJohn O'Brien
John O'Brien
MYM. Yamada
M. Yamada
The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them. REM sleep behavior disorder, severe neuroleptic sensitivity, and reduced striatal dopamine transporter activity on functional neuroimaging are given greater diagnostic weighting as features suggestive of a DLB diagnosis. The 1-year rule distinguishing between DLB and Parkinson disease with dementia may be difficult to apply in clinical settings and in such cases the term most appropriate to each individual patient should be used. Generic terms such as Lewy body (LB) disease are often helpful. The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that these are associated with the clinical DLB syndrome. Finally, the authors suggest patient management guidelines including the need for accurate diagnosis, a target symptom approach, and use of appropriate outcome measures. There is limited evidence about specific interventions but available data suggest only a partial response of motor symptoms to levodopa: severe sensitivity to typical and atypical antipsychotics in ∼50%, and improvements in attention, visual hallucinations, and sleep disorders with cholinesterase inhibitors.

1 August 2000 in European Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
JSJörg B. Schulz
Jörg B. Schulz
JLJörg Lindenau
Jörg Lindenau
JSJan Seyfried
Jan Seyfried
JDJohannes Dichgans
Johannes Dichgans
There is significant evidence that the pathogenesis of several neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, Friedreich's ataxia and amyotrophic lateral sclerosis, may involve the generation of reactive oxygen species and mitochondrial dysfunction. Here, we review the evidence for a disturbance of glutathione homeostasis that may either lead to or result from oxidative stress in neurodegenerative disorders. Glutathione is an important intracellular antioxidant that protects against a variety of different antioxidant species. An important role for glutathione was proposed for the pathogenesis of Parkinson's disease, because a decrease in total glutathione concentrations in the substantia nigra has been observed in preclinical stages, at a time at which other biochemical changes are not yet detectable. Because glutathione does not cross the blood–brain barrier other treatment options to increase brain concentrations of glutathione including glutathione analogs, mimetics or precursors are discussed.

1 March 2012 in NeuroImage
Verified
Journal Article
Closed access
CRC. Rottschy
C. Rottschy
RLRobert Langner
Robert Langner
IDI. Dogan
I. Dogan
KRK. Reetz
K. Reetz
ALA.R. Laird
A.R. Laird
SES.B. Eickhoff
S.B. Eickhoff

1 December 1993 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
ABAllen C. Bowling
Allen C. Bowling
JSJorg B. Schulz
Jorg B. Schulz
RBRobert H. Brown
Robert H. Brown
MBM. Flint Beal
M. Flint Beal

20 October 2004 in JAMA
Verified
Journal Article
Open access
PDF file
ALAndreas R. Luft
Andreas R. Luft
SMSandy McCombe-Waller
Sandy McCombe-Waller
JWJill Whitall
Jill Whitall
LFLarry W. Forrester
Larry W. Forrester
RMRichard Macko
Richard Macko
DHDaniel F. Hanley
Daniel F. Hanley
Hemiparesis represents the dominant functionally limiting symptom in 80% of patients with acute stroke.1 Within 2 to 5 months after a stroke, patients recover a variable degree of function, depending on the magnitude of the initial deficit.1 Several studies have demonstrated that recovery is associated with reorganization of central nervous system networks.2,3 Functional brain imaging of paretic movement during the recovery period has shown recruitment of cortex immediately adjacent to the stroke cavity along with intact cortical areas within the lesioned and in the uninjured contralesional hemisphere.4,5 The pattern of recruitment depends on the severity of impairment,6 lesion location,7 and time since stroke.8 The factors that initiate and maintain cortical reorganization are not known. Imaging data suggest that circuitry in motor cortices on both sides of the brain is modified during recovery.2

8 February 2004 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MMMaria-Céu Moreira
Maria-Céu Moreira
SKSandra Klur
Sandra Klur
MWMitsunori Watanabe
Mitsunori Watanabe
ANAndrea H Németh
Andrea H Németh
IBIsabelle Le Ber
Isabelle Le Ber
MKMichel Koenig
Michel Koenig
Ataxia-ocular apraxia 2 (AOA2) was recently identified as a new autosomal recessive ataxia. We have now identified causative mutations in 15 families, which allows us to clinically define this entity by onset between 10 and 22 years, cerebellar atrophy, axonal sensorimotor neuropathy, oculomotor apraxia and elevated alpha-fetoprotein (AFP). Ten of the fifteen mutations cause premature termination of a large DEAxQ-box helicase, the human ortholog of yeast Sen1p, involved in RNA maturation and termination.